Sarcoidosis: Comprehensive Guide to Pathophysiology, Imaging Diagnosis, and Advanced Management
Introduction to Sarcoidosis
Figure Review
Figure 1. Gallium-67 Nuclear Medicine Scan
Symmetrical increased Gallium-67 uptake in bilateral parotid and lacrimal glands (“Panda sign”) and right paratracheal and bilateral hilar lymph nodes (“Lambda sign”), consistent with active sarcoidosis.
This characteristic pattern strongly supports the diagnosis of sarcoidosis, rather than mumps, Paget’s disease, septic emboli, or tuberculosis. The “Panda sign” reflects salivary and lacrimal gland involvement, while the “Lambda sign” represents bilateral hilar and right paratracheal lymphadenopathy.
Correct Diagnosis: Sarcoidosis
Figure 2. Cardiac Sarcoidosis SPECT Image
Patchy focal radiotracer uptake within the myocardium on SPECT imaging, indicating inflammatory activity consistent with cardiac sarcoidosis.
This imaging pattern reflects granulomatous infiltration of the myocardium and is clinically significant due to the risk of arrhythmias, conduction block, heart failure, and sudden cardiac death.
Pathophysiology of Sarcoidosis
Sarcoidosis pathophysiology involves immune dysregulation, genetic susceptibility, and environmental triggers.
1. Immunologic Mechanisms
Activation of CD4+ Th1 lymphocytes
Increased IL-2 and IFN-γ production
Macrophage activation
Formation of non-caseating granulomas
Granuloma formation occurs due to persistent antigenic stimulation. Unlike tuberculosis, sarcoidosis granulomas lack central necrosis.
Recent molecular studies suggest:
Dysregulated mTOR signaling
Elevated TNF-α levels
Aberrant macrophage polarization
2. Genetic Factors
Strong association with HLA-DRB1 alleles
Familial clustering observed
Higher prevalence in Scandinavian and African-American populations
3. Environmental Triggers
Potential triggers include:
Inorganic dust exposure
Bioaerosols
Infectious antigens (mycobacterial peptides)
Despite extensive research, no single causative antigen has been definitively identified.
Epidemiology of Sarcoidosis
Sarcoidosis epidemiology varies geographically:
Incidence: 5–40 per 100,000 persons
Peak onset: 20–50 years
Female predominance in many populations
Higher severity in African-descended populations
In Korea and Japan, incidence is lower compared to Northern Europe, but cardiac sarcoidosis appears relatively more prevalent.
Clinical Presentation of Sarcoidosis
Sarcoidosis clinical presentation ranges from asymptomatic to life-threatening.
1. Pulmonary Sarcoidosis (Most Common)
Persistent dry cough
Dyspnea
Chest discomfort
Bilateral hilar lymphadenopathy
2. Constitutional Symptoms
Fatigue
Fever
Weight loss
3. Extrapulmonary Manifestations
| Organ | Manifestations |
|---|---|
| Skin | Erythema nodosum, lupus pernio |
| Eyes | Uveitis |
| Heart | Arrhythmias, AV block |
| Nervous system | Neurosarcoidosis |
| Liver | Hepatomegaly |
Imaging Features of Sarcoidosis
Sarcoidosis imaging is central to diagnosis and staging.
Chest X-Ray Staging
Stage 0 – Normal
Stage I – Bilateral hilar lymphadenopathy
Stage II – Lymphadenopathy + pulmonary infiltrates
Stage III – Pulmonary infiltrates only
Stage IV – Pulmonary fibrosis
CT Findings
Perilymphatic nodules
Upper lobe predominance
Fibrotic changes in chronic disease
Gallium-67 Scan
Gallium scan sarcoidosis findings include:
Panda sign
Lambda sign
Assessment of inflammatory activity
Although less frequently used today compared to FDG PET, Gallium scanning remains historically significant and educationally valuable.
SPECT Imaging in Cardiac Sarcoidosis
Cardiac SPECT imaging detects:
Patchy myocardial inflammation
Perfusion defects
Disease activity
SPECT is particularly helpful when evaluating:
Ventricular arrhythmias
AV block
Unexplained cardiomyopathy
Differential Diagnosis of Sarcoidosis
Differential diagnosis includes:
Tuberculosis
Lymphoma
Hypersensitivity pneumonitis
Granulomatosis with polyangiitis
Fungal infections
A biopsy demonstrating non-caseating granulomas is required for confirmation.
Diagnosis of Sarcoidosis
Sarcoidosis diagnosis requires:
Compatible clinical presentation
Imaging findings
Histopathologic confirmation
Exclusion of alternative causes
Laboratory findings may include:
Elevated ACE levels
Hypercalcemia
Elevated soluble IL-2 receptor
However, none are diagnostic alone.
Treatment of Sarcoidosis
Sarcoidosis treatment depends on organ involvement.
First-Line Therapy
Systemic corticosteroids
Second-Line Agents
Methotrexate
Azathioprine
Mycophenolate mofetil
Biologic Therapy
TNF-α inhibitors (Infliximab)
Cardiac Sarcoidosis
Immunosuppressive therapy
Implantable cardioverter-defibrillator (ICD) if indicated
Prognosis of Sarcoidosis
Sarcoidosis prognosis is variable:
60–70% spontaneous remission
10–20% chronic progressive disease
1–5% mortality (cardiac/neurosarcoidosis)
Poor prognostic factors:
Cardiac involvement
Pulmonary fibrosis
African ancestry
Persistent hypercalcemia
Quiz
Question 1. Which Gallium-67 scan pattern is characteristic of sarcoidosis?
A. Diffuse skeletal uptake
B. Solitary lung nodule
C. Panda sign
D. Renal cortical uptake
E. Ring-enhancing lesion
Answer: C. Explanation: The Panda sign represents increased uptake in lacrimal and salivary glands typical of sarcoidosis.
Question 2. Which cytokine predominates in sarcoidosis granuloma formation?
A. IL-4
B. IL-10
C. IFN-γ
D. IL-17
E. IL-5
Answer: C. Explanation: Th1-driven IFN-γ production is central to granuloma formation.
Question 3. The most serious complication of cardiac sarcoidosis is:
A. Pericardial effusion
B. Mitral stenosis
C. Sudden cardiac death
D. Aortic aneurysm
E. Pulmonary embolism
Answer: C. Explanation: Ventricular arrhythmias due to granulomatous infiltration can cause sudden cardiac death.
Conclusion
Sarcoidosis remains a complex systemic granulomatous disease requiring multidisciplinary management.
Imaging modalities such as Gallium scan sarcoidosis imaging and Cardiac SPECT in sarcoidosis provide critical insight into inflammatory activity and organ involvement.
Early diagnosis and tailored treatment significantly improve the prognosis of sarcoidosis.
For clinicians and researchers alike, understanding the pathophysiology, epidemiology, clinical presentation, imaging features, diagnosis, differential diagnosis, treatment, and prognosis of sarcoidosis is essential for optimizing patient outcomes.
References
[1] G. Baughman et al., “Clinical practice. Sarcoidosis,” N Engl J Med, vol. 357, pp. 2153–2165, 2007.
[2] A. Iannuzzi et al., “Sarcoidosis,” N Engl J Med, vol. 357, pp. 2153–2165, 2007.
[3] WASOG Guidelines, “Diagnosis and Management of Sarcoidosis,” 2020.
[4] HRS Expert Consensus Statement on Cardiac Sarcoidosis, 2014.
[5] ATS Clinical Practice Guideline on Sarcoidosis, 2020.
[6] Judson MA, “The Clinical Features of Sarcoidosis,” Clin Chest Med, 2015.
[7] Statement on Sarcoidosis, ATS/ERS/WASOG, Am J Respir Crit Care Med, 1999.
Comments
Post a Comment